Mainstream

Neogenomics outlines revised 2025 outlook with 9% 10% revenue growth target amid pharma headwinds and pantracer launch

NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch

NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch

Post ContentneoRead More

You might also be interested in reading iShares 7-10 Year Treasury Bond ETF declares monthly distribution of $0.3032.

July 29, 2025
In Mainstream